Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.

OBJECTIVE: Vaccinations are highly essential to control infectious diseases and epidemics. Presently, the entire world faces a challenging crisis of "Severe Acute Respiratory Diseases Coronavirus 2 (SARS-CoV-2), also known as the COVID-19 pandemic". The impact of vaccines at national levels to reduce the SARS-CoV-2 cases and deaths are unclear, and people have concerns about the effectiveness of vaccines in real-world settings. This study's objective was to examine the effect of the "Pfizer/BioNTech and Oxford/AstraZeneca" vaccines to prevent SARS-CoV-2 cases and deaths in Saudi Arabia. MATERIALS AND METHODS: In this retrospective cohort study, we collected data on SARS-CoV-2 cases and deaths from the date of the first case of SARS-CoV-2 in Saudi Arabia March 2, 2020, to the date of launching the vaccination campaign on December 14, 2020; and from December 15, 2020, to September 8, 2021. We recorded the World Health Organization data and Ministry of Health of Saudi Arabia to evaluate the impact of the "Pfizer/BioNTech, (BNT162b2 mRNA) and Oxford/AstraZeneca (AZD1222)" vaccine against SARS-CoV-2 cases and deaths before and after the vaccination campaign in Saudi Arabia. RESULTS: Saudi Arabia launched the "Pfizer/BioNTech and Oxford/AstraZeneca" vaccination campaign against SARS-CoV-2 on December 14, 2020. In Saudi Arabia, before the vaccination campaign from March 2, 2020, to December 14, 2020, the mean daily SARS-CoV-2 cases were 1235.60, daily deaths were 22.70, that significantly reduced (p=0.0001) compared to the period after the vaccination campaign from December 15, 2020, to September 8, 2021, in which the daily cases fell to 692.08, and daily deaths fell to 9.48 (p=0.0001). CONCLUSIONS: In Saudi Arabia, Pfizer/BioNTech and Oxford/AstraZeneca vaccinations significantly reduced the number of SARS-CoV-2 cases and deaths after the vaccination compared to the period before the vaccination campaign at country levels. The study findings demonstrate that vaccination and adherence to nonpharmaceutical intervention can better control the COVID-19 pandemic.

Evaluation of locally-administered controlled-release doxycycline hyclate gel in smokers and non-smokers in the management of periodontitis: An Indian study

Purpose: To assess the clinical and biological effect of locally-administered controlled-release 10 % doxycycline hyclate gel in smokers and non-smokers for the management of periodontitis. Methods: Forty periodontitis patients were enrolled in this study from December 2012 to February 2013 at the Department of Periodontology and Implantology of the Institute of Dental Sciences and Dental Unit of Rohilkhand Medical College, Bareilly, Uttar Pradesh (UP), India. For each patient, probing pocket depth (PPD), clinical attachment level (CAL), plaque index (PI), gingival index (GI), and sulcular bleeding index (SBI) were recorded. Changes in microbial counts were assessed by measuring colony-forming units (CFU) of three major periodontal pathogens. Clinical and microbial parameters were recorded at baseline and one month after scaling and root planing plus controlled local drug delivery of 10 % doxycycline hyclate gel in smokers and non-smokers. Results: A statistically significant change (p < 0.01) in PPD was observed among smokers between baseline (4.26 +/- 0.12mm) and re-evaluation at one month (3.20 +/- 0.11) with a change of 24.88 %. A statistically significant difference was found between smokers and non-smokers in PPD at the end of a 1-month re-evaluation (p < 0.05). None of the other parameters showed improvement in smokers following treatment. Conclusion: These results indicate that 10 % doxycycline hyclate gel, when administered locally into the periodontal pocket, shows clinical and microbial improvement, among smokers and non-smokers, in the management of periodontitis. Therefore, 10 % doxycycline gel is potentially an effective therapeutic strategy in the management of periodontitis.